Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients

Inclusion Criteria:

• Provide written informed consent prior to participation in the Study

• Be at least 18 years of age and weigh at least 41 kilogram (kg)

• Be anticipated by the Investigator to require multi-day (target is five days) use ofIV treatment either because of having a "nothing by mouth" (NPO) status having amedical condition that makes oral intake difficult having a medical condition thatrequires IV treatment

• Be willing to undergo 5 days of treatment with IV acetaminophen for the treatment ofpain or fever (defined as a core temperature greater than or equal to 38 degreescelsius). Note that Subjects have a slightly less than 15% chance (one in seven) ofbeing assigned to the Control Group and receiving standard of care treatment, but noIV APAP.

• Have the ability to read and understand the Study procedures and have the ability tocommunicate meaningfully with the Study Investigator and staff

• If a female of child bearing potential, have a negative pregnancy test within 48 hoursof randomization

Exclusion Criteria:

• Has a significant medical disease, laboratory abnormality or condition that, in theInvestigator's judgment, could compromise the Subject's welfare or would otherwisecontraindicate Study participation

• Is expected to have difficulty in communicating with the Study staff or completingStudy requirements (including follow up visits)

• Has known hypersensitivity to acetaminophen or the inactive ingredients (excipients)of IV acetaminophen or any contraindication to receiving acetaminophen

• Has impaired liver function, e.g., Alanine aminotransferase (ALT) greater than orequal to 3 times the upper limit of normal (ULN), bilirubin greater than or equal to 3times ULN, known active hepatic disease (e.g., hepatitis), evidence of clinicallysignificant chronic liver disease or other condition affecting the liver (e.g.,alcoholism as defined by DSM-IV, cirrhosis or chronic hepatitis)

• Has participated in an interventional clinical Study (investigational or marketedproduct) within 30 days of Study entry